semaglutide for mash Receives FDA Approval Treatment of Semaglutide Significantly Improves Steatohepatitis, Fibrosis

This medication mimics the incretin hormone produced by the intestines, encouraging insulin secretion in response to meals while also inhibiting glucagon release

People microdosing GLP-1s do so for: Mitigating Side Effects: Standard doses of GLP-1 agonists can cause significant gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation (2)

Some people may experience symptoms like nausea, vomiting, diarrhea, or constipation when taking the medication

Clinical data demonstrates significant weight loss, metabolic improvements, and reduction in liver fat compared to placebo

Direct-to-patient distribution models like this are likely to evolve beyond GLP-1s to include other medication categories like migraine therapies and womens/mens health, CenterWells Sollberger said

Declaration of Helsinki: ethical principles for medical research involving human subjects